| 000 | 01828 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516014100.0 | ||
| 264 | 0 | _c20110531 | |
| 008 | 201105s 0 0 eng d | ||
| 022 | _a1873-2402 | ||
| 024 | 7 |
_a10.1016/j.biopsych.2010.10.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKometer, Michael | |
| 245 | 0 | 0 |
_aThe 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. _h[electronic resource] |
| 260 |
_bBiological psychiatry _cMar 2011 |
||
| 300 |
_a399-406 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aCluster Analysis |
| 650 | 0 | 4 |
_aConsciousness Disorders _xpsychology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aElectroencephalography _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHallucinogens _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aNeuropsychological Tests |
| 650 | 0 | 4 |
_aOccipital Lobe _xdrug effects |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 650 | 0 | 4 |
_aPerceptual Closure _xphysiology |
| 650 | 0 | 4 | _aPhotic Stimulation |
| 650 | 0 | 4 |
_aPsilocybin _xpharmacology |
| 650 | 0 | 4 | _aPsychometrics |
| 650 | 0 | 4 |
_aReaction Time _xphysiology |
| 650 | 0 | 4 |
_aReceptor, Serotonin, 5-HT1A _xdrug effects |
| 650 | 0 | 4 |
_aReceptor, Serotonin, 5-HT2A _xdrug effects |
| 650 | 0 | 4 |
_aSchizophrenia _xcomplications |
| 650 | 0 | 4 |
_aSerotonin Receptor Agonists _xpharmacology |
| 650 | 0 | 4 |
_aVisual Cortex _xdrug effects |
| 700 | 1 | _aCahn, B Rael | |
| 700 | 1 | _aAndel, David | |
| 700 | 1 | _aCarter, Olivia L | |
| 700 | 1 | _aVollenweider, Franz X | |
| 773 | 0 |
_tBiological psychiatry _gvol. 69 _gno. 5 _gp. 399-406 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.biopsych.2010.10.002 _zAvailable from publisher's website |
| 999 |
_c20418271 _d20418271 |
||